Related references
Note: Only part of the references are listed.Recent advances in novel targeted therapies for HER2-positive breast cancer
Conleth G. Murphy et al.
ANTI-CANCER DRUGS (2012)
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Elizabeth A. Mittendorf et al.
CANCER (2012)
Effective modulation of CD4+CD25+high regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2
Guangxian Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Comments on therapeutic cancer vaccines
Vladimir Vonka
IMMUNOTHERAPY (2012)
Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer
Thomas Decker et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Erika Hamilton et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
Vivian L. Weiss et al.
PLOS ONE (2012)
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
Bei Wang et al.
BREAST CANCER RESEARCH (2012)
Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach
Nathalie Garcon et al.
BIODRUGS (2011)
High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer
Ozcan Met et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Use of Booster Inoculations to Sustain the Clinical Effect of an Adjuvant Breast Cancer Vaccine From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Jarrod P. Holmes et al.
CANCER (2011)
Vaccination of patients with cutaneous melanoma with telomerase-specific peptides
Robert E. Hunger et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
Purevdorj B. Olkhanud et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mahsa Mohebtash et al.
CLINICAL CANCER RESEARCH (2011)
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines
Linda C. Benavides et al.
EXPERT REVIEW OF VACCINES (2011)
Influenza virosomes as a vaccine adjuvant and carrier system
Christian Moser et al.
EXPERT REVIEW OF VACCINES (2011)
Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials
Elizabeth A. Mittendorf et al.
EXPERT REVIEW OF VACCINES (2011)
Immunoglobulin A A next generation of therapeutic antibodies?
Jantine E. Bakema et al.
MABS (2011)
Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
David Miles et al.
ONCOLOGIST (2011)
Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-α in a model of metastatic breast cancer
Michael S. Sabel et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations
Bas Kreike et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
Ursula Wiedermann et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
DNA vaccination strategies for anti-tumour effective gene therapy protocols
Emanuela Signori et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Anti-HER2 vaccines: new prospects for breast cancer therapy
Maha Zohra Ladjemi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer
Jose Baselga et al.
CLINICAL BREAST CANCER (2010)
Tumors as Organs: Complex Tissues that Interface with the Entire Organism
Mikala Egeblad et al.
DEVELOPMENTAL CELL (2010)
MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy
Shifang Yuan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Strategies for Cancer Vaccine Development
Matteo Vergati et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
DNA Vaccines: Developing New Strategies against Cancer
Daniela Fioretti et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
Hakan Norell et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Adjuvants for cancer vaccines
Thomas W. Dubensky et al.
SEMINARS IN IMMUNOLOGY (2010)
A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility
Paul Roepman et al.
BMC MEDICAL GENOMICS (2009)
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity
Andrew L. Coveler et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?
Antoinette R. Tan et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
The effects of trastuzumab on the CD4+CD25+FoxP3+and CD4+IL17A+T-cell axis in patients with breast cancer
C. Horlock et al.
BRITISH JOURNAL OF CANCER (2009)
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice
Simona Vertuani et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
Fariba Mozaffari et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients
Daniele Generali et al.
CLINICAL CANCER RESEARCH (2009)
Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9
Luigi Aurisicchio et al.
CLINICAL CANCER RESEARCH (2009)
An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non-Small-Cell Lung Cancer
Paul Roepman et al.
CLINICAL CANCER RESEARCH (2009)
A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors
Matthew M. Seavey et al.
CLINICAL CANCER RESEARCH (2009)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
CD4(+) T cells in antitumor immunity: utility of an li-Key HER2/neu hybrid peptide vaccine (AE37)
Elizabeth A. Mittendorf et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
C. Gravalos et al.
ANNALS OF ONCOLOGY (2008)
Human tumor antigens to and sialyl Tn arise from mutations in Cosmc
Tongzhong Ju et al.
CANCER RESEARCH (2008)
Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel
Shinichi Kageyama et al.
CANCER SCIENCE (2008)
Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease
Vincent G. Brichard et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER-2/neu peptide (AE37) vaccine
Jarrod P. Holmes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular origins of cancer - Cancer immunology
Olivera J. Finn
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
A. M. Krieg
ONCOGENE (2008)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice
C. Curcio et al.
CANCER GENE THERAPY (2008)
DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice
M. Mkrtichyan et al.
GENE THERAPY (2008)
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers
Lupe G. Salazar et al.
CLINICAL IMMUNOLOGY (2007)
Immunology and breast cancer: Therapeutic cancer vaccines
Giuseppe Curigliano et al.
BREAST (2007)
Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice
Stefan Wagner et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Enhancing efficacy of therapeutic vaccinations by combination with other modalities
James L. Gulley et al.
VACCINE (2007)
Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation
Reinhard Obst et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen lapuleucel-T: Results of a phase I study in immunologic and clinical activity in HER-2-overexpressing breast cancer
John W. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Development of vaccines for high-risk ductal carcinoma in situ of the breast
Brian J. Czerniecki et al.
CANCER RESEARCH (2007)
Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu
Joan T. Garrett et al.
JOURNAL OF IMMUNOLOGY (2007)
Cutting edge:: Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response
Joke M. M. den Haan et al.
JOURNAL OF IMMUNOLOGY (2007)
HER2-specificT-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan
Shigehisa Kitano et al.
CLINICAL CANCER RESEARCH (2006)
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
Gaynor J. Bates et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Combined chemoimmunotherapy of solid tumours: Improving vaccines?
Anna K. Nowak et al.
ADVANCED DRUG DELIVERY REVIEWS (2006)
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
Elizabeth A. Mittendorf et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial
Elizabeth A. Mittendorf et al.
CANCER (2006)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
GE Peoples et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu -: a new method of epitope definition
AB Riemer et al.
MOLECULAR IMMUNOLOGY (2005)
The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules:: implications for tumor immune escape
I Algarra et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients
ML Disis et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants
SY Chang et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
IM Svane et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu
AB Riemer et al.
JOURNAL OF IMMUNOLOGY (2004)
Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine
ML Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The changing global patterns of female breast cancer incidence and mortality
F Bray et al.
BREAST CANCER RESEARCH (2004)
Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu
J Jasinska et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
AW Burgess et al.
MOLECULAR CELL (2003)
Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine
YP Luo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses
NK Dakappagari et al.
JOURNAL OF IMMUNOLOGY (2003)
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines
ML Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies:: Implications for vaccine design
YL Yip et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
